HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Suppression of familial adenomatous polyposis by CP-31398, a TP53 modulator, in APCmin/+ mice.

Abstract
p53 mutations occur in a large number of human malignancies. Mutant p53 is unable to affect downstream genes necessary for DNA repair, cell cycle regulation, and apoptosis. The styrylquinazoline CP-31398 can rescue destabilized mutant p53 expression and promote activity of wild-type p53. The present study examines chemopreventive effects of CP-31398 on intestinal adenoma development in an animal model of familial adenomatous polyposis. Effects were examined at both early and late stages of adenoma formation. Effects of CP-31398 on early-stage adenomas were determined by feeding 7-week-old female C57BL/6J-APC(min) (heterozygous) and wild-type C57BL/6J mice with American Institute of Nutrition-76A diets containing 0, 100, or 200 ppm of CP-31398 for 75 days. To examine activity toward late-stage adenomas, CP-31398 administration was delayed until 15 weeks of age and continued for 50 days. During early-stage intervention, dietary CP-31398 suppressed development of intestinal tumors by 36% (P < 0.001) and 75% (P < 0.0001), at low and high dose, respectively. During late-stage intervention, CP-31398 also significantly suppressed intestinal polyp formation, albeit to a lesser extent than observed with early intervention. Adenomas in treated mice showed increased apoptotic cell death and decreased proliferation in conjunction with increased expression of p53, p21(WAF1/CIP), cleaved caspase-3, and cleaved poly(ADP-ribose) polymerase. These observations show for the first time that the p53-modulating agent CP-31398 possesses significant chemopreventive activity in vivo against intestinal neoplastic lesions in genetically predisposed APC(min/+) mice. Chemopreventive activity of other agents that restore tumor suppressor functions of mutant p53 in tumor cells is currently under investigation.
AuthorsChinthalapally V Rao, Malisetty V Swamy, Jagan M R Patlolla, Levy Kopelovich
JournalCancer research (Cancer Res) Vol. 68 Issue 18 Pg. 7670-5 (Sep 15 2008) ISSN: 1538-7445 [Electronic] United States
PMID18794156 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Cdkn1a protein, mouse
  • Cyclin-Dependent Kinase Inhibitor p21
  • Pyrimidines
  • Tumor Suppressor Protein p53
  • Poly(ADP-ribose) Polymerases
  • Caspase 3
  • CP 31398
Topics
  • Adenomatous Polyposis Coli (drug therapy, genetics, metabolism, pathology)
  • Animals
  • Apoptosis (drug effects)
  • Caspase 3 (metabolism)
  • Cell Growth Processes (drug effects)
  • Cyclin-Dependent Kinase Inhibitor p21 (genetics, metabolism)
  • Dose-Response Relationship, Drug
  • Female
  • Genes, APC
  • Intestinal Neoplasms (drug therapy, genetics, metabolism, pathology)
  • Mice
  • Mice, Inbred C57BL
  • Poly(ADP-ribose) Polymerases (metabolism)
  • Pyrimidines (pharmacology)
  • Tumor Suppressor Protein p53 (genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: